J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

In alleged psychiatric malpractice, the courts ruled that the burden of a patient’s criminal actions does not fall on their treating psychiatrist.

TD Cowen analyst Joseph Thome has maintained their bullish stance on ITCI stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Johnson & Johnson is working on a bid for $10bn neuroscience drugmaker Intra-Cellular Therapies, in what would be the biggest ...

The Central Bank of Kenya (CBK) has been ordered to pay a former cleaner Sh5 million for discrimination after she was fired ...

BRITISH actor and comedian Tony Slattery has died at the age of 65. His family revealed the cause of his death was a heart ...

The annual briefing provided an opportunity to assess 10-year trends in youth mental health and discuss solutions Wisconsin ...

IgG MoDE Degraders: BHV-1300 Phase 1 completing last remaining dose cohorts with the optimized subcutaneous formulation with expected completion in 1H 2025. BHV-1310 first-in-human study anticipated ...